SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

Search

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

51.65 0.19

Overview

Share price change

24h

Current

Min

50.65

Max

51.95

Key metrics

By Trading Economics

Income

-57M

32M

Sales

199M

434M

P/E

Sector Avg

19.7

73.239

EPS

0.457

Dividend yield

2.1

Profit margin

7.411

Employees

2,197

EBITDA

40M

138M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+43.2% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.10%

3.06%

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

-691M

2.7B

Previous open

51.46

Previous close

51.65

News Sentiment

By Acuity

25%

75%

59 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

Laboratorios Farmaceuticos Rovi SA Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2025, 22:45 UTC

Top News

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 Mar 2025, 23:54 UTC

Market Talk

Nikkei May Rise After Monday's Selloff -- Market Talk

31 Mar 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Global Equities Roundup: Market Talk

31 Mar 2025, 22:33 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 Mar 2025, 22:28 UTC

Earnings

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke Swings to Loss for 2024 >000002.SZ

31 Mar 2025, 21:47 UTC

Top News

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 Mar 2025, 21:44 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 Mar 2025, 21:21 UTC

Market Talk

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 Mar 2025, 21:18 UTC

Top News

Copper Is 2025's Hottest Commodity -- Update

31 Mar 2025, 21:09 UTC

Top News

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 Mar 2025, 21:02 UTC

Earnings

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 Mar 2025, 21:01 UTC

Earnings

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 Mar 2025, 20:37 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 Mar 2025, 20:17 UTC

Top News

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 Mar 2025, 20:13 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 Mar 2025, 20:03 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 Mar 2025, 19:09 UTC

Market Talk

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 Mar 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 Mar 2025, 18:54 UTC

Market Talk

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 Mar 2025, 18:40 UTC

Market Talk

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 Mar 2025, 18:34 UTC

Market Talk

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 Mar 2025, 18:28 UTC

Market Talk

Gold Climbs to Close Out Quarter -- Market Talk

31 Mar 2025, 18:03 UTC

Top News

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

43.2% upside

12 Months Forecast

Average 73.75 EUR  43.2%

High 82 EUR

Low 65.5 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

50.45 / 52.35Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

59 / 386 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.